NYSE - Delayed Quote
USD
Qiagen N.V. (QGEN)
43.47
-0.39
(-0.89%)
At close: September 4 at 4:00:03 PM EDT
43.47
0.00
(0.00%)
After hours: September 4 at 7:30:07 PM EDT
Trade QGEN on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for QGEN
- Previous Close
43.86 - Open
43.19 - Bid 43.39 x 30000
- Ask 43.38 x 60000
- Day's Range
42.79 - 43.66 - 52 Week Range
32.53 - 57.82 - Volume
1,922,186 - Avg. Volume
2,881,182 - Market Cap (intraday)
8.976B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
22.07 - EPS (TTM)
1.97 - Earnings Date Nov 4, 2026
- Forward Dividend & Yield 0.35 (0.80%)
- Ex-Dividend Date Jul 7, 2026
- 1y Target Est
46.07
Recent News
View More
Performance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
QGEN
2.46%
S&P 500 (^GSPC)
12.75%
1-Year Return
QGEN
6.76%
S&P 500 (^GSPC)
18.71%
3-Year Return
QGEN
1.26%
S&P 500 (^GSPC)
70.93%
5-Year Return
QGEN
22.30%
S&P 500 (^GSPC)
70.18%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 8/27/2026
-
Market Cap
9.13B
-
Enterprise Value
9.88B
-
Trailing P/E
22.47
-
Forward P/E
12.05
-
PEG Ratio (5yr expected)
1.10
-
Price/Sales (ttm)
4.34
-
Price/Book (mrq)
2.69
-
Enterprise Value/Revenue
4.75
-
Enterprise Value/EBITDA
14.18
Financial Highlights
Profitability and Income Statement
-
Profit Margin
19.49%
-
Return on Assets (ttm)
5.87%
-
Return on Equity (ttm)
11.93%
-
Revenue (ttm)
2.1B
-
Net Income Avi to Common (ttm)
409.32M
-
Diluted EPS (ttm)
1.97
Balance Sheet and Cash Flow
-
Total Cash (mrq)
793.5M
-
Total Debt/Equity (mrq)
49.25%
-
Levered Free Cash Flow (ttm)
372.86M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
288.50
-1.65%
Mkt Cap
13.773B
Industry
Diagnostics & Research
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Innovation and Execution to Drive Above-Market Growth for Qiagen
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
RatingPrice Target -
Qiagen: CEO Change Amid Takeover Speculation; Shares Undervalued
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
RatingPrice Target -
Qiagen Earnings: Customer Capital Spending Weakness Persists; Growth Pillars Remain Resilient
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
RatingPrice Target -
Qiagen Earnings: Guidance Cut as Geopolitical Tensions Weaken Demand; Shares Undervalued
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
RatingPrice Target
